BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$80.70 USD
-1.43 (-1.74%)
Updated Apr 30, 2024 03:51 PM ET
After-Market: $80.73 +0.03 (0.04%) 4:08 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMRN 80.70 -1.43(-1.74%)
Will BMRN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Other News for BMRN
Biotech Sector: M&A Fuels Renewed Excitement
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth Potential
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
Biotech Alert: Searches spiking for these stocks today